Novo Nordisk has undertaken significant legal actions to safeguard U.S. patients from unauthorized compounded versions of its semaglutide-based medications, Ozempic® and Wegovy®. These efforts aim to ensure patient safety by preventing the distribution of unapproved and potentially unsafe versions of these drugs. Novo Nordisk
This post seeks to explain the legal actions Novo Nordisk has taken, the decisions made by U.S. courts and the FDA, and the reasons behind these decisions in a way that’s easy to understand for the general public, but this should not be taken as legal advice or a substitute for professional guidance. Readers are encouraged to consult official court documents, FDA announcements, or speak with a licensed attorney or healthcare provider for information specific to their situation. Always do your own research and verify details through trusted, authoritative sources.
In early 2025, the U.S. Food and Drug Administration (FDA) determined that the shortage of semaglutide injectable medicines had been resolved. This decision was based on Novo Nordisk’s stable and growing supply of FDA-approved Ozempic® and Wegovy®, which now meet or exceed current and projected nationwide patient demand. Consequently, the FDA’s resolution ended the legal basis for compounding pharmacies to produce or sell compounded versions of these medications, with rare exceptions (Reuters, Novo Nordisk News).
On April 24, 2025, a Texas federal court ruled in favor of Novo Nordisk and the FDA by denying a compounding trade association’s motion to freeze the FDA’s decision. The court’s ruling left in place the FDA’s determination that all doses of Wegovy® and Ozempic® are fully available nationwide. This decision allows the FDA to take immediate enforcement action against 503A pharmacies compounding unauthorized versions of semaglutide and sets a May 22, 2025, deadline for 503B outsourcing facilities to cease production (Reuters).
Novo Nordisk has filed 111 federal lawsuits across 32 states against entities marketing and selling unauthorized compounded semaglutide products. These legal actions aim to protect patients from potentially harmful and unapproved versions of semaglutide. In several cases, courts have issued permanent injunctions prohibiting these entities from falsely claiming their products are equivalent to Novo Nordisk’s FDA-approved medications (Fierce Pharma, Novo Nordisk News).
A report by the Brookings Institution highlighted that many compounded semaglutide products in the U.S. are made using synthetic APIs sourced from overseas manufacturers, particularly in China. These manufacturers often lack external quality reference standards and, in some cases, have not been inspected by the FDA. This raises significant concerns about the safety and efficacy of compounded semaglutide products (Brookings Institution, Novo Nordisk News).
Law enforcement agencies and state attorneys general have issued warnings about the dangers of unauthorized compounded semaglutide products. For instance, the Ohio Attorney General sent letters to 14 entities, warning them against deceiving patients into believing that compounded drugs are FDA-approved. Similarly, the Illinois Attorney General issued cease-and-desist letters to med spas advertising name-brand medications but offering unapproved versions (Novo Nordisk News).
To meet the growing demand and reduce the appeal of illegal copies, Novo Nordisk has:
These efforts underscore Novo Nordisk’s dedication to ensuring that patients have access to safe, effective, and FDA-approved treatments (Reuters).
Novo Nordisk’s legal and public health initiatives are centered on protecting patients from the risks associated with unauthorized compounded semaglutide products. With the FDA confirming the end of the semaglutide shortage, patients are encouraged to use only FDA-approved medications prescribed by licensed healthcare professionals.
At ThinMD Med Spa, we are deeply committed to staying at the forefront of medical innovation and patient safety. Our team continuously monitors emerging research, legal developments, and regulatory updates to ensure that every therapy we offer – including semaglutide-based treatments – is backed by sound science and administered responsibly. Whether compounded or non-compounded, all of our therapies are delivered in full alignment with FDA guidelines and industry best practices, because our patients deserve nothing less than the highest standards of care.
For more information about Novo Nordisk’s efforts to protect patients, visit semaglutide.com.
